Lilly buys in another PI3Kα inhibitor
Scorpion's STX-478 becomes at least the third shot Lilly has taken at PI3Kα.
Scorpion's STX-478 becomes at least the third shot Lilly has taken at PI3Kα.
The UK company buys IRDx for $1bn.
In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.
The latest B7-H4 ADC shows activity only in biomarker-positive patients.
The company is to start a first-line phase 3 breast cancer trial of gedatolisib, as second-line data approach.
And, in developing ZL-6201, it wants to succeed where AbbVie disappointed.
But the timeline for a US green light is less clear, and the group has a cash crisis.
First-in-human trial initiations include Biocytogen's DM002 and Day One's DAY301.
An anti-integrin β6 ADC and a CDK4 inhibitor shoot for bigger markets.
Two masked bispecific antibodies, licensed for $100m, produce promising early data.